Review article: novel therapeutic options for chronic hepatitis C

Papatheodoridis, George V.

doi:10.1111/j.1365-2036.2008.03644.x

Cited by 30 publications

(35 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although PEG-IFN and RBV have always been included in HCV treatments, their limited efficacy and frequent side effects have encouraged the search for a better alternative 8. Direct-acting antiviral agents, which have a different approach in targeting the life cycle of HCV, have been developed and approved by the US FDA 29,30…”

Section: Discussionmentioning

confidence: 99%

Effect of Chronic Hepatitis C Virus Treatment by Combination Therapy on Cardiovascular System

Biomy

Abdelshafy

Ahmed

et al. 2017

Clin Med Insights Cardiol

View full text Add to dashboard Cite

BACKGROUNDThe prevalence of hepatitis C virus (HCV) in Egypt is quite high, and the combined oral direct-acting antiviral agents (DAAs) may have impressive results.OBJECTIVETo assess the cardiovascular effects of DAAs in patients with HCV.METHODSA total of 170 patients with HCV were divided into 2 groups: first group (100 patients) received triple combination therapy (pegylated interferon alfa, sofosbuvir, and ribavirin, whereas the second group (70 patients) received dual combination therapy (sofosbuvir and simeprevir). Group 1 patients were followed up for 1 year more than 3 visits, whereas group 2 patients were followed up for 6 months more than 2 visits; and the end point of the study was the development of a major cardiovascular event (eg, congestive heart failure, echocardiographic evidence of left ventricular dysfunction, occurrence of significant arrhythmias, or acute coronary syndrome). The following parameters were accomplished: medical history and clinical examination, electrocardiogram, echo-Doppler study, and laboratory investigations.RESULTSNo significant differences were found between the 2 study groups regarding demographic criteria. None of the both group patients had developed any major cardiac event. No significant changes were observed regarding ST-T wave abnormalities, arrhythmias, or QT interval. None of the both group patients developed echocardiographic regional wall motion abnormalities at baseline or at study end. Systolic function parameters showed minute nonsignificant changes over study visits. Diastolic function parameters showed nonsignificant changes between baseline and 6-month and 12-month visits.CONCLUSIONSThe DAAs used in combination regimen with interferon or used orally in combination do not significantly affect the cardio-vascular system.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of Chronic Hepatitis C Virus Treatment by Combination Therapy on Cardiovascular System

Biomy

Abdelshafy

Ahmed

et al. 2017

Clin Med Insights Cardiol

View full text Add to dashboard Cite

show abstract

“…Antisense oligonucleotides research is considered a very promising technology for use in the development of drugs with both high target specificity and reduced side effects. Studies have demonstrated antisense inhibition of viral gene expression in biochemical assays, in cultured cells and in animal models [85][86][87][88][89][90][91][92][93][94][95][96][97][98][99][100][101][102]. Currently, there is ongoing antisense oligonucleotides research targeting human cytomegalovirus and human immunodeficiency virus, which is being evaluated in clinical trials.…”

Section: Delivery Of Antisense Therapymentioning

confidence: 99%

“…A targeted novel approach of delivering antisense therapy and other entities which are typically too problematic to deliver may be instrumental. Therefore achieving a combination of targeted delivery of oligonucleotides, other genetic disrupters and other viral targets not normally feasible with current systems may be advantageous [31,32,[85][86][87][88][89][90][91][92][93][94][95][96][97][98][99][100][101][102].…”

Section: Viral Infectionsmentioning

confidence: 99%

“…Current treatments have not demonstrated promising results, thus demanding innovative treatments [85][86][87][88][89][90][91][92][93][94][95][96][97][98][99][100][101][102]. One promising antiviral strategy implemented against HCV is the use of RNA interference (RNAi), a specific gene silencing process mediated by small interfering RNA (siRNA) duplexes.…”

Section: Delivery Of Antisense Therapymentioning

confidence: 99%

See 1 more Smart Citation

Carbon nanotubes in drug delivery: focus on infectious diseases

Rosen

Elman

2009

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

Carbon nanotubes have the potential to address the challenges of combating infectious agents by both minimizing toxicity by dose reduction of standard therapeutics and allowing a multiple payload capacity to achieve both targeted activity and combating infectious strains, resistant strains in particular. One of their unique characteristics is the network of carbon atoms in the nanometer scale, allowing the creation of nano-channels via cellular membranes. This review focuses on the characterization, development, integration and application of carbon nanotubes as nanocarrier-based delivery systems and their appropriate design for achieving the desired drug delivery results in the different areas of infectious diseases. While a more extensive toxicological and pharmacological profile must be obtained, this review will focus on existing research and pre-clinical data concerning the potential use of carbon nanotubes.

show abstract

“…Although major achievements in hepatitis C treatment have been accomplished during the past decade, the future therapeutic approach will certainly rely on specifically targeted antiviral therapies (STAT-C) against essential viral proteins, especially for subjects who had no response to or had experienced relapses after receipt of current combination treatment with pegylated interferon and ribavirin [7]. Indeed, these new molecules have shown very good potency in in vitro assays, particularly against HCV-1 strains.…”

mentioning

confidence: 98%

Natural Variability of NS3 Protease in Patients Infected with Genotype 4 Hepatitis C Virus (HCV): Implications for Antiviral Treatment Using Specifically Targeted Antiviral Therapy for HCV

et al. 2009

View full text Add to dashboard Cite

To analyze the genetic diversity of the NS3 gene in patients infected with hepatitis C virus (HCV) genotype 4 (HCV-4) and to assess the possible effects of the gene polymorphism (or variability) on drug susceptibility, 43 NS3 gene sequences were determined for 53 selected patients with HCV-4 infection. NS3 sequencing, like NS5B sequencing, allowed correct subtype determination. Most residues that were located within the catalytic triad or the NS4-binding region or that were involved in metal binding were highly conserved and identical to those found in HCV genotype 1. Compared with HCV genotype 1, all HCV-4 NS3 protein presented V36L and C16T residue changes that could potentially reduce antiprotease activity. The efficacy of antiprotease in HCV-4-infected patients remains to be proven in large clinical trials.

show abstract

Review article: novel therapeutic options for chronic hepatitis C

Abstract: SUMMARY BackgroundThe efficacy of treatment against hepatitis C virus has improved, but it is still far from ideal. Thus, new antihepatitis C virus therapies are required.

Cited by 30 publications

References 95 publications

Effect of Chronic Hepatitis C Virus Treatment by Combination Therapy on Cardiovascular System

Effect of Chronic Hepatitis C Virus Treatment by Combination Therapy on Cardiovascular System

Carbon nanotubes in drug delivery: focus on infectious diseases

Natural Variability of NS3 Protease in Patients Infected with Genotype 4 Hepatitis C Virus (HCV): Implications for Antiviral Treatment Using Specifically Targeted Antiviral Therapy for HCV

Contact Info

Product

Resources

About